Confirmation of antibodies against hepatitis C virus by recombinant immunoblot: Is it really an improvement to abandon it?

Calvo, Ana Avellón; Mayo, José

doi:10.1016/j.eimc.2019.05.008

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-HCV and anti-HIV total antibodies are considered the standard screening test for HCV and HIV infection 4 . Chronic HCV infection should be confirmed with RNA detection 8 , 9 while HIV antibody reactivity should be confirmed by an additional two serology reactive test results for a HIV-positive diagnosis 10 . HBsAg is the earliest indicator (besides HBV DNA detection) of HBV acute or chronic infection, may be present before symptoms appear, and can thus be used to detect active infection 11 .…”

Section: Introductionmentioning

confidence: 99%

HCV, HIV AND HBV rapid test diagnosis in non-clinical outreach settings can be as accurate as conventional laboratory tests

Muñoz-Chimeno,

Valencia,

Rodriguez-Recio

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Point of care rapid diagnostic tests (POC-RDT) for Hepatitis C virus (HCV), Human Immunodeficiency virus (HIV) and Hepatitis B virus (HBV), are ideal for screening in non-clinical outreach settings as they can provide immediate results and facilitate diagnosis, allowing high risk population screening. The aim of this study was to compare POC-RDT with laboratory conventional tests. A total of 301 vulnerable evaluable subjects (drug users, migrants and homeless population) were recruited at a mobile screening unit in outreach settings in Madrid. Fingerprick whole blood capillary samples were tested using the SD BIOLINE HCV POC-RDT, Determine HIV Early Detect and Determine HBsAg 2, and the results were assessed against the LIAISON XL HCV, HIV and Murex-HBsAg-Quant, reference assays, respectively. The feasibility and user satisfaction of the POC-RDT were evaluated through a questionnaire. The resolved sensitivity and resolved specificity and their 95% confidence intervals (95% CI) were as follows, respectively: SD-BIOLINE-HCV: 98.8% (95% CI 93.4, 100.0) and 100.0% (95% CI 98.3, 100.0); Determine HIV Early Detect: 100% (95% CI 85.2, 100.0) and 100% (95% CI 98.7, 100); and Determine HBsAg 2: 66.7% (95% CI 9.4, 99.2) and 100.0% (95% CI 98.7, 100.0). As expected, the number of subjects with a confirmed positive result for HBsAg was very low (n = 4). Therefore, the analytical sensitivity has been evaluated in addition: The Determine HBsAg 2 test demonstrated 100% sensitivity for standard concentrations ≥ 0.125 IU/mL. The subject questionnaire yielded positive feedback for most subjects. The POC-RDT fingerprick blood collection method was well received, and the tests demonstrated a comparable clinical performance with conventional tests in outreach settings and vulnerable high-risk populations.

show abstract

Section: Introductionmentioning

confidence: 99%